GSK secures FDA approval for Jemperli to treat endometrial cancer
FDA approved Jemperli for mismatch repair-deficient (dMMR) recurrent or advanced endometrial cancer that has progressed after a prior…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
13 Feb 23
FDA approved Jemperli for mismatch repair-deficient (dMMR) recurrent or advanced endometrial cancer that has progressed after a prior…
08 Feb 23
Forxiga is already approved in more than 100 countries worldwide, to treat patients with type-2 diabetes (T2D), HFrEF…
06 Feb 23
Trodelvy is a Trop-2 directed antibody-drug conjugate, indicated for previously treated patients with metastatic hormone receptor (HR)-positive, human…
02 Feb 23
The US FDA approval of Jesduvroq is based on results from the ASCEND-D trial, which evaluated the efficacy…
30 Jan 23
Jaypirca is the first BTK inhibitor specifically approved for patients with mantle cell lymphoma previously treated with a…
27 Jan 23
The EC approval is based on results from Phase 3 DESTINY-Breast04 clinical trial, in which Enhertu reduced the…
23 Jan 23
The Japanese drugmaker intends to complete the clinical and regulatory activities required to resume dosing in the FORTIS…
20 Jan 23
The Bruton’s tyrosine kinase inhibitor showed superior efficacy in first-line and relapsed/refractory treatment settings in two global phase…
19 Jan 23
With the IND clearance, the biotechnology company is set to launch a phase 1 trial of the recombinant…
16 Jan 23
Tezspire is a human monoclonal antibody that inhibits the action of TSLP, an important epithelial cytokine responsible for…